Pith. sign in

REVIEW 1 cited by

Using path signatures to predict a diagnosis of Alzheimer's disease

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 1808.05865 v1 pith:OKZKZFTM submitted 2018-08-16 q-bio.QM stat.AP

classification q-bio.QMstat.AP
keywords datapathalzheimerdiseasefeaturessignaturedistinguishencode
verification ladder T0 review T1 audit T2 compute T3 formal
0 comments
read the original abstract

The path signature is a means of feature generation that can encode nonlinear interactions in the data as well as the usual linear features. It can distinguish the ordering of time-sequenced changes: for example whether or not the hippocampus shrinks fast, then slowly or the converse. It provides interpretable features and its output is a fixed length vector irrespective of the number of input points so it can encode longitudinal data of varying length and with missing data points. In this paper we demonstrate the path signature in providing features to distinguish a set of people with Alzheimer's disease from a matched set of healthy individuals. The data used are volume measurements of the whole brain, ventricles and hippocampus from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The path signature method is shown to be a useful tool for the processing of sequential data which is becoming increasingly available as monitoring technologies are applied.

Discussion (0). Continue with ORCID to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. Deep Learning for Estimating Synaptic Health of Primary Neuronal Cell Culture

    eess.IV 2019-08 conditional novelty 5.0 of 10

    A fine-tuned ResNet18 classifies images of Aβ-treated versus untreated neurons with 99.6% accuracy and screens 36 compounds, none of which showed a protective effect.

Pith tools